Genmab — December 2014
-
hvad sagde han om poma solsen?
-
jeg kørte kun et meget stort VTD (1000 patient studiet) fordi de skulle være sikker på at dara ikke påvirkede stam cell transplantationen
-
han siger at normalen er 30% CR i frontline. Med dara har vi 50+% i Relapsed !!!
-
det viser hvor god dara er
-
BTD studiet could well - og så siger han bagefter "really well" blive det første label.
han er mere opmistist omkring filing nu -
120281 . de 10 jeg snakkede om var 10 aktive duobody programmer
-
richardson siger han har en patient i BTD studiet som har responderet flot
-
ja mener han sagde 301 studiet. er det ikke BTF studiet
-
sorry 503
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind